CN118019538A - 用于降解BTK并具有降低的IMiD活性的双官能化合物 - Google Patents

用于降解BTK并具有降低的IMiD活性的双官能化合物 Download PDF

Info

Publication number
CN118019538A
CN118019538A CN202280061966.9A CN202280061966A CN118019538A CN 118019538 A CN118019538 A CN 118019538A CN 202280061966 A CN202280061966 A CN 202280061966A CN 118019538 A CN118019538 A CN 118019538A
Authority
CN
China
Prior art keywords
atoms
alkyl
compound
heterocycloalkyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280061966.9A
Other languages
English (en)
Chinese (zh)
Inventor
C·桂杜奇
M·诺维斯基
J·珀维尔斯
R·朗特里
陈莹晓
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nulex Therapeutics
Original Assignee
Nulex Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nulex Therapeutics filed Critical Nulex Therapeutics
Publication of CN118019538A publication Critical patent/CN118019538A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280061966.9A 2021-07-14 2022-07-13 用于降解BTK并具有降低的IMiD活性的双官能化合物 Pending CN118019538A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221905P 2021-07-14 2021-07-14
US63/221905 2021-07-14
PCT/US2022/037029 WO2023287928A1 (en) 2021-07-14 2022-07-13 Bifunctional compounds for degrading btk with diminished imid activity

Publications (1)

Publication Number Publication Date
CN118019538A true CN118019538A (zh) 2024-05-10

Family

ID=82799901

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280061966.9A Pending CN118019538A (zh) 2021-07-14 2022-07-13 用于降解BTK并具有降低的IMiD活性的双官能化合物

Country Status (9)

Country Link
US (1) US20240336595A1 (https=)
EP (1) EP4370123A1 (https=)
JP (1) JP2024525797A (https=)
KR (1) KR20240035837A (https=)
CN (1) CN118019538A (https=)
AU (1) AU2022310182A1 (https=)
CA (1) CA3225367A1 (https=)
IL (1) IL309796A (https=)
WO (1) WO2023287928A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120590386A (zh) * 2025-05-30 2025-09-05 北京科莱博医药开发有限责任公司 一种喹喔啉类蛋白降解剂及其制备方法和应用
CN120617259A (zh) * 2025-06-05 2025-09-12 南昌大学第一附属医院 Btk protac化合物nx-5948的新应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
US12582722B2 (en) 2019-02-13 2026-03-24 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
JP2024524480A (ja) * 2021-07-01 2024-07-05 ハンチョウ、ヘルズン、セラピューティクス、カンパニー、リミテッド ブルトン型チロシンキナーゼ及びその突然変異体の分解剤、組成物並びにそれらの応用
CA3236073A1 (en) 2021-10-26 2023-05-04 Robert J. Brown Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
WO2025162210A1 (zh) * 2024-02-04 2025-08-07 上海超阳药业有限公司 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途
WO2026005533A1 (ko) * 2024-06-27 2026-01-02 한미약품 주식회사 신규한 이종이작용기 단백질 분해제 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120590386A (zh) * 2025-05-30 2025-09-05 北京科莱博医药开发有限责任公司 一种喹喔啉类蛋白降解剂及其制备方法和应用
CN120617259A (zh) * 2025-06-05 2025-09-12 南昌大学第一附属医院 Btk protac化合物nx-5948的新应用
CN120617259B (zh) * 2025-06-05 2026-04-10 南昌大学第一附属医院 Btk protac化合物nx-5948的应用

Also Published As

Publication number Publication date
IL309796A (en) 2024-02-01
WO2023287928A1 (en) 2023-01-19
KR20240035837A (ko) 2024-03-18
EP4370123A1 (en) 2024-05-22
AU2022310182A1 (en) 2024-02-01
US20240336595A1 (en) 2024-10-10
CA3225367A1 (en) 2023-01-19
JP2024525797A (ja) 2024-07-12

Similar Documents

Publication Publication Date Title
CN118019538A (zh) 用于降解BTK并具有降低的IMiD活性的双官能化合物
US12600732B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US11866442B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
EP4055019B1 (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
US20240279202A1 (en) Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use
CN118019539A (zh) 用于降解BTK并具有增强的IMiD活性的双官能化合物
AU2022370351A1 (en) Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
CN117916231A (zh) 用于抑制或降解靶蛋白的化合物、包含其的组合物、其制备方法及其使用方法
HK40081936A (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
BR122023025072A2 (pt) Usos de compostos bifuncionais para degradar btk por meio da via da ubiquitina-proteossoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination